How dotalizumab (Jemperli) works

Dotalizumab (Jemperli) is an immunotherapy drug. Its main function is to enhance the immune system's attack on cancer cells by inhibiting the signaling pathway on the PD-1 (programmed death1) receptor. The following is the main mechanism of action of dotalizumab:

1.Relieving immunosuppression: The mechanism of action of dotalizumab is based on the principle of immune checkpoint inhibition. PD-1 is an immune checkpoint receptor that exists on the surface of immune cells, such as T cells (an important immune cell). Its main function is to inhibit the activity of TT cells to avoid excessive immune response. However, in some cases, cancer cells can exploit this mechanism to evade the immune system by overexpressing PD-L1, a ligand for PD-1. Dotalizumab works by preventing the binding of PD-1 and PD-L1 to relieve the inhibition of T cells, allowing them to regain their ability to attack cancer cells.

2.Enhance immune response: The use of dotalizumab increases the ability of T cells to recognize and attack cancer cells. This helps improve the immune system's immune response and enhances its ability to recognize and eliminate cancer cells.

3.Long-lasting anti-cancer effects: Treatment with dotalizumab may result in long-lasting anti-cancer effects. Some patients retain immune memory of the cancer cells after treatment ends, meaning the immune system is still able to recognize and fight the cancer cells' reappearance even after treatment ends.

Dotalizumab is not currently on the market in China, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.